Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327924 | 0.84 | CYP1A2 (0.34) | CYP1A2POLBHCRTR1HCRTR2 | |
| SCHEMBL31691992 | 0.81 | IDH1 (0.33) | CYP1A2POLBHCRTR1HCRTR2 | |
| SCHEMBL20890572 | 0.81 | MAP4K1 (0.36) | CYP1A2POLBHCRTR1HCRTR2 | |
| SCHEMBL13806057 | 0.78 | ALOX15 (0.35) | NPC1MAPTRAB9A | |
| SCHEMBL8171795 | 0.78 | IDH1 (0.42) | CYP1A2POLB | |
| SCHEMBL18857239 | 0.77 | SYK (0.35) | NPC1MAPTRAB9A | |
| SCHEMBL22460209 | 0.77 | TDP1 (0.35) | NPC1MAPTRAB9A | |
| SCHEMBL20428031 | 0.74 | ADRB1 (0.37) | — | |
| SCHEMBL896386 | 0.74 | PARP1 (0.35) | CYP1A2POLBHCRTR1HCRTR2 | |
| SCHEMBL18857412 | 0.73 | HDAC8 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099252-A1 | NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099252-A1 | NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS | TUBB6, TUBB1, TUBA1C | CYP1A2 4837/4885POLB 2018/4885HCRTR1 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.